Effects of the XXXX inhibitor @entity585 on serum levels of gonadal, adrenal, and hypophyseal hormones and its clinical significance: a prospective clinical study.

@entity1 @entity251 @entity323 @entity1369 @entity586 @entity585 @entity1067 @entity2494 @entity134 @entity10831 @entity701 @entity1486 @entity250
In the present study, we investigated the effects of a @entity134 @entity10831 inhibitor, @entity585 , when given orally (5 mg/day), on the serum levels of gonadal, hypophyseal, and adrenal hormones and the clinical significance of these effects. Forty-eight @entity1 with a mean age of 63 (range 49-81) were included in the study. All @entity1 had symptoms of @entity1067 . Serum levels of @entity251 , @entity586 , follicle-stimulating hormone (FSH) luteinizing hormone (LH), prolactin, @entity1369 , @entity701 , and @entity2494 were determined before the study. The degree of symptoms in each patient and serum @entity1486 levels were determined together with uroflowmetric studies. Sexual status of the @entity1 was also assessed with a self-administered questionnaire. All @entity1 received @entity585 , 5 mg/day, for 6 weeks. All of the above mentioned studies were repeated at month 3 and month 6. All of the @entity1 had baseline hormonal values within the normal range. At month 3, the @entity586 level decreased by 60%, while the @entity251 level increased by 15%. FSH and LH levels decreased by 24% and 16%, respectively. The changes in the serum levels of these hormones were further evident at month 6. No significant changes were noted in the serum levels of prolactin, @entity1369 , @entity701 , and @entity2494 . Thirty-six @entity1 (75%) were judged to be potent before the treatment. @entity585 caused @entity323 in 8 @entity1 (22%) by month 3 and in 12 (33%) by month 6. A substantial improvement was noted in symptoms of @entity1067 in all patients. The serum @entity1486 level decreased by 42% and 50% at month 3 and at month 6, respectively. Continued administration of @entity585 , 5 mg/day alters the serum levels of @entity251 , @entity586 , FSH, and LH significantly. @entity585 also causes @entity250 in a substantial number of @entity1 and should be offered with caution to @entity1 who have an active sexual life.
